single gene. It is an important mechanism for regulating gene expression and may be utilized by 40-60% of human genes (1) (2) (3) (4) . Thus, the estimated 25,000 to 30,000 genes of the human genome can generate a much larger number of proteins. Regulation of alternative splicing occurs in both a tissue-and developmental-specific manner, resulting in alterations in the structure and function of critical proteins. Altered splicing regulation can also be of widespread importance in the etiology of human disease (5) (6) (7) .
The protein 4.1 gene family serves as an excellent model for investigating the regulation of alternative splicing. The four genes that comprise the family (4.1R, 4.1G, 4.1B, and 4.1N) display a remarkable array of highly regulated, tissuespecific splicing events. These alternative splicing events facilitate expression of distinct isoforms of 4.1 protein in cells of erythroid, epithelial, neural, and muscle origin (8) (9) (10) (11) (12) (13) (14) ; thus, they provide opportunities for understanding the mechanisms that regulate alternative splicing in several different cell types. To date, mechanistic studies have focused predominantly on erythroid cells, in which 4.1R protein is a structural component of the erythrocyte plasma membrane and is important for structural integrity and stability of the membrane skeleton. In differentiating erythroid progenitor cells, a dramatic switch in pre-mRNA splicing results in a physiologically important functional change in the encoded structural protein isoforms (15, 16) . 4 .1R protein in early progenitors, derived from transcripts in which E16 is skipped, exhibits a low affinity for spectrin and actin; in contrast, E16 inclusion in late stage erythroblasts generates a high affinity isoform (17) (18) (19) (20) . E16 splicing is influenced by multiple regulatory elements located not only in the exon, but also in the flanking introns, and at the splice sites themselves (21) (22) (23) . One component of the regulatory machinery in erythroid cells is a stagespecific repression of E16 inclusion, mediated by binding of hnRNP A/B proteins to exonic splicing silencer (ESS) element(s) located within the exon. Repression occurs in early erythroid progenitors, which express high levels of hnRNP A/B proteins, and repression is subsequently relieved by a substantial down-regulation of hnRNP A/B expression in later stage erythroblasts (23) . Reduction in the level of splicing inhibitory proteins thus appears to be a critical feature of the physiological E16 splicing switch in erythroid cells.
In this paper, we describe a second mechanism whereby E16 splicing efficiency can be regulated, in this case via the interaction of splicing activator protein(s) with positive regulatory elements in the downstream intron. Our results demonstrate phylogenetic conservation of UGCAUG splicing enhancer motifs downstream of E16, specific binding of these elements to both Fox-1 and Fox-2 splicing factor proteins, and UGCAUG-dependent stimulation of E16 splicing by both of these proteins in functional splicing assays. These findings support the emerging model of Fox protein splicing factors as important components of the cellular machinery that switches on splicing of critical alternative exons at appropriate times during development and differentiation by acting at highly specific UGCAUG intron enhancers (24) (25) (26) (27) .
MATERIAL AND METHODS
Nomenclature. The splicing factors described in this paper have been reported independently by multiple laboratories in different contexts and with different names. Fox-1 is also known as ataxin 2 binding protein (A2BP1; (28)) or hexaribonucleotide binding protein 1 (HRNBP1; (29)); Fox-2 has been designated as hexaribonucleotide binding protein 2 (HRNBP2; (29) ), RBM9 (30), or Fxh (31) . Both Fox genes encode multiple isoforms via alternative splicing; e.g., see cDNAs AF094849, AF109106, and AF229057 and recent publications (27, 32, 33 Mammalian expression clones for mFox-2α (BC002124) and mFox-2β (BC027263) were obtained from Research Genetics. The human Fox-1α cDNA (AF094849) was cloned in one of our laboratories (JCW) and inserted into the expression vector pcDNA3.1-Myc-His(-) between the XbaI and HindIII sites. siRNAs. Duplex siRNAs obtained from Dharmacon were as follows: Fox-2 siRNA duplex 1: sense strand, 5'-GACAGUAUAUGGUG-CAGUCUU; antisense strand, 5'-PGACUGCA-CCAUAUACUGUCUU. Fox-2 siRNA duplex 2: sense strand, 5'-CGAGAAUAGUGCUGAUG-CAUU; antisense strand, 5'-PUGCAUCAG-CACUAUUCUCGUU. Splicing analysis. HeLa cells were transfected with plasmid DNAs using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Transfections with siRNA were performed for 24 hrs in 6 well culture dishes using 200 pmol of siRNA. Total RNA was isolated 72 hrs later using RNeasy columns (Qiagen). First strand cDNA was synthesized from the isolated RNA with Superscript II reverse transcriptase (Invitrogen) and an exon 17 3' primer. PCR analysis of spliced 4.1 pre-mRNA was performed using DNA primers located in exon 13 (forward primer: 5'-AGCCATTGCTCAGAGTCAGG-3') and exon 17 (reverse primer: 5'-GCGAATTCCCGGATTCAGT-3') of the 4.1 minigene. Immunoblot analysis. HeLa cell protein extracts for immunoblot analysis were prepared by lysis in Novex Tris-Glycine-SDS-buffer (Invitrogen) + DTT and boiled for 10 min. Anti-Fox-2 antiserum (Washington Biotechnology) was raised in rabbits against a synthetic peptide, GVPHTQDYAGQT. This peptide was selected on the basis of its conservation between mouse and human Fox-2 and its divergence from mouse and human Fox-1. The Fox-2 antibody used in these experiments was affinity purified against a synthetic peptide (GenScript Corporation) by using Affi-Gel ® 10 (BioRad) according to the manufacturer's instructions, and was diluted 1:100 in milk blotto/PBS-T solution. For the detection of actin the antibody (Cytoskeleton) was used at 1:5000 dilution. The secondary antibody was goat-antirabbit IgG conjugated to HRP (1:5000 dilution). For signal detection, the Western Lightning Chemiluminescence Reagent Kit was employed (Perkin Elmer Life Sciences).
Mouse erythroblasts were obtained from the spleens of mice infected with the Friend virus, anemia-inducing strain (FVA), and cultured as previously described (34, 35) . Cells differentiate from proerythroblasts to enucleated reticulocytes over ~44-48 hrs in culture. Protein was extracted from the cultured cells and analyzed by immunoblot analysis. SELEX analysis of Fox-1 binding specificity. For systematic evolution of ligands by exponential enrichment (SELEX) (36) , 500 µg of hFox-1α-myc-his protein, isolated from a baculovirus/SF9-expression system, was coupled to 1 ml NHSactivated Sepharose 4B beads (Pharmacia). The oligonucleotides used for SELEX were identical or similar to those used previously (37, 38) : SELN40:
5'-GGCACTATTTATATCAACTAGAACTACTGG ATCCG(N) 40 TTGGTA-CCCAATTCGCCCTATAGTGAGTCGTATTA-3' (N 40 representing 40 nucleotides of random sequence) SELF:
5'-TAATACGACTCACTATAGGGCGAATTGGG TACCAA-3' (for PCR) SELREV1: 5'-GGCACTATTTATATCAAC-3' (for reverse transcription) SELREV2:
5'-GGCACTATTTATATCAACTAGAACTACTGG ATCCG-3' (for PCR). The SELEX was performed as previously described with some modification (39) . 100 µg of SELF and 300 µg of SELN40 were annealed as the template for in vitro transcription using RiboProbe ® in vitro Transcription System (Promega). The synthesized RNA was extracted with phenol/chloroform, precipitated, and dissolved in Binding Buffer (0.1 M NaCl, 50 mM Tris-HCl, pH 8.0, 14.4 mM β-mercaptoethanol) containing 4mg/ml tRNA. Approximately 1 mg of RNA was loaded onto the 1 ml hFox1α-Sepharose 4B column equilibrated with Binding Buffer, mixed and mildly rotated at room temperature for 10 min. The column was washed with 10 ml of Binding Buffer and eluted with 10 ml of 0.1 M NaCl, MTPBS (16 mM Na 2 HPO 4 , 4 mM NaH 2 PO 4 , pH 7.3) followed by 10 ml of 1.0 M NaCl, MTPBS. The first 10 fractions (0.5 ml each) eluted by 1 M NaCl, MTPBS were collected, and the RNA was precipitated and dissolved in DEPC-treated H 2 O. One fifth of the RNA was reverse transcribed and amplified (22 cycles of 94 °C 45 sec, 65 °C 45 sec and 72 °C 45 sec). The amplified PCR product was resolved by 2% agarose gel electrophoresis. Fractions 2, 3 and 4 eluted with 1 M NaCl, MTPBS were pooled as templates for the next round of SELEX. Beginning with the fourth round, the concentration of NaCl was increased to 0.4 M in both the Binding Buffer and the first elution buffer. A total of seven rounds of SELEX were performed. The PCR product of the final round was digested with KpnI and BamHI and cloned to pBluescript vector. Individual clones were selected and sequenced.
In vitro synthesis of hFox-1 and mFox-2 proteins.
Human Fox-1α cDNA from clone AF094849 was amplified using primers hBP1-S (5'-CACCAGCATGCTGGCGTCTCAAGGAGTTCT C-3') and hBP1-AS (5'-TTAGTATGGAGCAAAACGGTTGTATCC-3') and cloned into the bacterial expression vector pEXP1-DEST (Invitrogen). The resulting hFox-1 construct, tagged at the N-terminus with the Express epitope and a six-histidine epitope, was synthesized by in vitro transcription/translation using Expressway Plus (Invitrogen) according to the manufacturer's instructions. Mouse Fox-2β cDNA was amplified from clone BC027263 using primers mBP2-S (5 (hexamer motifs are underlined and mutations represented in lower case). Binding experiments were performed essentially as previously described (23) . Briefly, recombinant hFox-1 or mFox-2 or hnRNP A1 was incubated with 100 pmol of biotinylated-RNA in splicing buffer for 30 min at 4 °C; RNA and associated proteins were then removed by binding to streptavidin-conjugated magnetic beads (Dynal) according to the manufacturer's instructions.
RESULTS

Binding specificity of mammalian Fox splicing factor proteins for the hexamer UGCAUG.
The consensus binding site of the zebrafish splicing factor, zFox-1, was defined as the pentamer GCAUG (24) . We independently cloned human Fox-1 (hFox-1) cDNA and examined its binding specificity via SELEX. As shown in Figure 1 , all of the winner sequences binding to hFox-1 contained at least one copy of the same pentamer recognized by zFox-1, and four contained two copies (sequence #6, 10, 26, 45). However, closer examination revealed that the great majority (45/47) of winner sequences for the human protein contained the hexamer UGCAUG, with an additional preference for U in the seventh position, i.e., UGCAUGU. These results are consistent with the recent structural analysis of a Fox-1-UGCAUGU complex (40) . This extended consensus binding site for hFox-1 may reflect evolutionary changes in the protein from fish to mammals. Alternatively, the minor difference in binding specificity may be due to the fact that the reported zebrafish Fox-1 is not the best ortholog of human Fox-1; i.e., a closer homolog with higher identity to the human Fox-1 RRM is encoded in the zebrafish genome (our unpublished observations). The powerful selection for winners with multiple UGCAUG elements may reflect cooperative binding of hFox-1 to regions with multiple binding sites. Notably, several of the natural occurrences of intronic UGCAUG or GCAUG splicing elements, including the 4.1 gene reported here, contain multiple elements (22, 32, (41) (42) (43) (44) . Figure 2 shows the domain structure of mammalian Fox-1 and two closely related Fox-2/ RBM9/HRNBP2 protein isoforms (hereafter called Fox-2) that are used for functional studies in this paper. The Fox-2 proteins possess different Cterminal domains and are derived from the same gene via alternative splicing, while Fox-1 is encoded by a separate gene. A C-terminal isoform of Fox-1 is also encoded by alternative splicing, but was not studied here. All of these mammalian Fox proteins are 100% identical in the RRM domain. Outside of the RRM domain, the proteins exhibit a reduced but still highly significant homology, except for the aforementioned alternative C-terminus. The functional splicing experiments described below demonstrate that these novel Fox proteins can promote exon inclusion in a UGCAUG-dependent manner. UGCAUG elements function as intron splicing enhancers for protein 4.1R exon 16. E16 in the 4.1R gene undergoes a splicing switch during erythropoiesis, being skipped in early progenitor cells and efficiently included at later stages (Figure 3, top) . Three repeats of the UGCAUG hexamer are located downstream of protein 4.1R E16 in the human and mouse genes, and mutations of these elements have been reported to decrease E16 inclusion (22) . As shown in Figure 3 , bottom panel, the presence of UGCAUG elements has been highly conserved in evolution, as 2-3 repeats are also located in the E16 proximal intronic regions of the rat, opossum, chicken, frog, and tetraodon (fish) 4.1R genes. In addition, two closely paralogous genes (4.1G and 4.1B) also possess UGCAUG repeats near alternative E16, although the surrounding intron sequences are otherwise quite divergent. These observations support a functional role for UGCAUG in regulating E16 splicing.
In order to test whether the conserved UGCAUG elements could function as enhancers or silencers of E16 splicing, several 4.1 pre-mRNA constructs possessing or lacking intronic hexamers were compared in functional splicing assays in transfected HeLa cells. As shown in figure 4 , the wild type transcript with three hexamers yielded a modest inclusion efficiency for E16 (43%) among its spliced products (lane 1 (Figure 4 , lane 4). Additional construct pairs containing wild type or mutant hexamers with different flanking nucleotides were also tested. While the wild type hexamers consistently yielded much higher exon inclusion efficiency than the comparable mutant hexamers, it was also clear that neighboring sequences could influence the magnitude of these effects (results not shown).
Analogous results were obtained in an in vitro splicing assay utilizing HeLa cell nuclear extract. E16 splicing efficiency in the wild type premRNA was dramatically reduced by deletion of the hexamer element; insertion of intact UGCAUG elements, but not mutated hexamers, rescued E16 splicing (data not shown). These results indicated that UGCAUG represents an intronic splicing enhancer for E16 splicing. Fox splicing factors promote E16 inclusion in a UGCAUG-dependent manner. The results above are consistent with a model in which Fox-1 and Fox-2 function as UGCAUG-dependent splicing factors that activate E16 splicing. This hypothesis was tested directly using a HeLa cell transfection strategy, asking whether Fox-1 or Fox-2 expression plasmids could stimulate E16 inclusion in 4.1 pre-mRNAs. Whereas the transfected wild type 4.1R construct alone exhibited only about 35% inclusion ( Figure 5A, 4.1 wt ), co-transfection with a full length Fox-1 or Fox-2 expression plasmid significantly increased E16 inclusion to 80% or to 70%, respectively. Additional transfection experiments revealed that despite the difference in C-terminal sequences of Fox-2α and Fox-2β, no significant difference in their ability to stimulate E16 splicing was observed (data not shown).
To test whether this observed Fox-protein enhancer activity was dependent on the presence of UGCAUG, further transfection experiments were performed. Pre-mRNA constructs containing or lacking the UGCAUG elements were co-transfected with the Fox-1 or Fox-2 expression plasmids. In contrast to the wild type pre-mRNA transfection, neither protein stimulated E16 splicing in premRNA substrates from which the hexamers were deleted (construct 4.1∆hex To confirm, that Fox-proteins are indeed expressed even in the constructs that show no E16 splicing, immunoblot analysis was performed ( Figure 5B ). As expected, in those cells that contain the Fox expression plasmid, a stronger Fox-1 or Fox-2 signal could be detected (indicated by an arrow) in comparison to all other transfection samples. This observation is not due to a larger amount of protein sample loaded on the gel as demonstrated by the actin detection ( Figure  5B , lower panels).
Together, these results suggest that both Fox proteins can rescue splicing in a UGCAUGdependent manner.
To further confirm the correlation of Foxproteins and E16 splicing, the effect on splicing was investigated when the protein expression was decreased by RNA interference. Therefore HeLa cells were transfected with the 4.1R minigene construct and siRNA duplexes against the Fox-2 gene. As shown in Figure 6 , co-transfection with siRNA duplex 1 led to a substantial reduction of E16 splicing in comparison to the wildtype premRNA. This result correlates with a decrease in Fox-2 expression, demonstrated by immunoblot ( Figure 6, middle Figure 7 , wild type intron 16 sequence pulled down both hFox-1 and mFox-2 (lanes "hex wt "); in contrast, mutant intron 16 RNA bound much lower quantities of either protein when assayed in parallel under identical conditions (lanes "hex mut "). The immunoblot using anti-hnRNP A1 serves as a control to demonstrate the integrity of the mutant oligonucleotide by virtue of its ability to bind hnRNP A1 similarly to the wild type RNA sequence. Notably, the mutant hexamer was defective both in binding to Fox-1/Fox-2 proteins, as well as in its enhancer activity for E16 splicing. This correlation strongly suggests that binding is directly relevant to enhancer activity.
Expression of Fox-2 in erythroid progenitor cells.
If Fox splicing factors play a role in activating the alternative splicing switch of E16 during erythroid differentiation, one would predict that Fox-2 expression levels should increase relative to that of the silencing factor hnRNP A1 (23) . This hypothesis was tested using the in vitro differentiation system for mouse erythroblasts isolated from the spleen of Friend virus-infected mice. As demonstrated earlier (23), E16 was excluded in RNA prepared from freshly isolated mouse erythroblasts, but included much more efficiently in RNA prepared from erythroblasts differentiated in the presence of erythropoietin (Figure 8, upper panel) . Protein extracts prepared at time points before and after the splicing switch were then immunoblotted with antibodies to both Fox-2 and hnRNP A1. Fox-2 was detected in the early erythroblasts, and levels changed little in mature cells after the splicing switch (Figure 8 , middle panel). In contrast, hnRNP A1 expression was significantly reduced after the splicing switch (Figure 8, lower panel) . These results reveal a substantial increase in the Fox-2:hnRNP A1 expression ratio, consistent with a physiological role for Fox-2 in regulating alternative splicing in late erythroid differentiation.
DISCUSSION
In this paper we have demonstrated that the Fox family of pre-mRNA splicing regulatory proteins, acting through UGCAUG intronic enhancer element(s), stimulates inclusion of alternative E16 in protein 4.1R pre-mRNA. These results provide new insights into the tissue-specific control of E16 splicing.
According to our working model, E16 splicing is an ordered process that begins with activation of the weak 5' splice site to facilitate removal of the downstream intron (21) . Use of this 5' splice site is inhibited directly or indirectly by binding of hnRNP A/B proteins to a well characterized silencer element in E16 (45), a putative second exonic site (our unpublished results), and potentially in the downstream intron as well ( Figure 9 ). Counterbalancing silencer activity are multiple enhancer elements in the purine-rich region of E16 (23) , in the downstream conserved region of the exon (46) , and in the downstream intron (22) . This suggests a multiple mode of regulation through dynamic antagonism (47) among opposing silencer and enhancer activities. Competition between Fox-1/Fox-2 and hnRNP A1 may be one important determinant of E16 splicing efficiency. Indeed, down-regulation of hnRNP A1 expression in late erythropoiesis relieves the splicing silencing activity to allow activation of E16 splicing (23) .
E16 is included not only in late stage erythroblasts, but also in muscle and in brain (9, 10, 13) . Therefore, there may be more than one mechanism for cells to integrate input from distinct differentiation signals to make a splicing decision to include E16. For example, while downregulation of hnRNP A1 is critical for E16 activation in erythroid cells, increased expression of Fox proteins in muscle and/or brain might be sufficient to switch on E16 splicing, independent of changes in cellular hnRNP A1 levels. Experiments exploring splicing factors interactions during muscle, and neural differentiation will be required to fully elucidate the splicing regulatory networks responsible for E16 regulation in various cell types. The observation that Fox-2 is significantly expressed in mouse erythroblasts suggests that it is a likely physiological activator of splicing in differentiating erythroid cells.
We propose that Fox-2 and its homologs play an important role in tissue-specific alternative splicing regulation in metazoan organisms, perhaps by functioning as part of a molecular switch acting at intronic UGCAUG enhancer elements to activate exon inclusion with the appropriate temporal and spatial specificity. This hypothesis is supported by the observations that UGCAUG is a critical regulatory element for proper tissue-specific splicing of calcitonin/CGRP, fibronectin, myosin II heavy chain-B, and c-src pre-mRNAs (41) (42) (43) (44) 48) ; that UGCAUG is statistically highly over-represented in the proximal downstream intron of many brain-and muscle-specific exons (25, 26, 49) ; that recombinant Fox-1 promotes muscle-specific splicing in a (U)GCAUG-dependent manner (24) ; and that Fox-2 enhances inclusion of an exon normally activated during erythroid differentiation (this paper). We speculate that the high binding specificity of Fox proteins is advantageous for splicing switch mechanism(s) designed to activate a limited repertoire of splicing events in response to a specific signaling mechanism in a specific cell type. Increased cellular levels of Fox splicing activity could then facilitate splicing switches in selected target transcripts, analogous to the stimulation of 4.1R E16 splicing that occurs in Fox-transfected HeLa cells, without effecting large general changes in splicing of many pre-mRNAs. The reported upregulation of Fox-2/ RBM9 in androgen-stimulated spinal motor neurons (31) suggests that it would be interesting to examine these cells for potential Fox-2-mediated activation of brain-specific exons reported earlier to possess proximal intronic UGCAUG elements (25) . Alternatively, decreased expression of antagonistic splicing inhibitor proteins could also activate splicing of Fox-responsive exons.
Fox proteins have a long evolutionary history, with close homologs in the genomes of C. elegans and Drosophila in addition to the zebrafish protein reported earlier. Likewise, the UGCAUG binding sites for Fox splicing factors are conserved not only in the proximal intron sequences of 4.1R E16 (Figure 3 ), but also adjacent to brain-specific exons from several vertebrate orders (25, 26) . It will be interesting to elucidate the full extent of Fox splicing factor function in the regulation of alternative splicing in various cell types in higher eukaryotes. Many questions remain to be addressed concerning the mechanism of action for this exciting new class of splicing regulators. One might speculate that Fox proteins function as adaptors to recruit spliceosomal machinery to a regulated exon (50) , perhaps synergizing with the action of exonic SR proteins, or with other intronic activators (e.g., (51) . Another vitally important issue relates to how Fox enhancer activity could be regulated in a tissue-specific manner, especially given the apparent expression of Fox proteins in multiple tissues. Do the same two (or a few) Fox genes mediate splicing switches in the appropriate temporal and spatial patterns during differentiation of various types of neural and muscle cells, as well as erythroid and potentially other cell types? These issues are likely to be as interesting as they are complex. Analogous to several other splicing factors, the Fox proteins exist as a mixture of alternatively spliced isoforms (27, 32, 33) . Future studies will likely reveal that tissue-specific expression of splicing co-activator proteins, and/or tissue-specific expression of functionally distinct Fox protein spliceoforms, is an essential requirement for precise developmental regulation. wt has four copies of the UGCAUG element reinserted, and RNA 4.1∆hex mut has four copies of a mutated element UGACUG reinserted into the deletion construct. Lower panel shows the splicing phenotype of each pre-mRNA. 4.1R minigenes were transfected into HeLa cells and the resulting spliced mRNAs were analyzed by RT-PCR using primers selective for the transfected sequence. Analysis of PCR products by electrophoresis shows a larger product (including E16) in the upper band and a smaller product (excluding E16) in the lower band. RT-PCR analysis of E16 splicing patterns in erythroblasts cultured for 24 and 45h (upper panel) and immunoblot analysis detecting Fox-2 (~48 kDa) and hnRNP A1 (~33 kDa) proteins before and after the splicing switch (lower panels). Actin serves as control for the amount of protein loaded on the gel. Fig. 9 . Regulatory elements and splicing factors that control exon 16 alternative splicing. Splicing enhancer elements in E16 (ESE) and the downstream intron (ISE) are proposed to stimulate splicing at the 5' splice site. Further, each enhancer is proposed to be antagonized by adjacent or overlapping silencer elements, including a known hnRNP A1-binding silencer element in the exon (ESS) and a putative silencer in the intron (ISS). Antagonism between the exonic elements has been reported earlier (20) . A second putative silencer element may be located in the 5' region of the exon (unpublished results). Three UGCAUG repeats are located within 140 nt downstream of E16. 
